0.215
3.21%
-0.0032
Mustang Bio Inc Aktie (MBIO) Neueste Nachrichten
Mustang Bio (NASDAQ:MBIO) Stock Quotes, Forecast and News Summary - Benzinga
Carmell, Mustang Bio, Revelation Biosciences Dominate Retail Biotech Talk As 2025 Kicks Off - MSN
Stock market news: Neumora Therapeutics down by 80.75% while N2OFF surged by 333.47% during mid day trading - Business Upturn
Mustang Bio files to sell 34.77M shares of common stock for holders - MSN
Mustang Bio Inc Still Hasn’t Convinced Analysts? - Stocks Register
Likelihood of Approval and Phase Transition Success Rate ModelMB-108 in Recurrent Malignant Glioma - GlobalData
Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Mustang Bio faces delisting, appoints new interim CFO - Investing.com
Mustang Bio's Interim CFO Resigns After 10 Months - MarketWatch
Mustang Bio Faces Nasdaq Delisting and Leadership Changes - TipRanks
Mustang Bio, Inc. Announces CFO Changes - Marketscreener.com
ARMISTICE CAPITAL, LLC Acquires New Stake in Mustang Bio Inc - GuruFocus.com
Fortress Biotech Inc. (FBIOP) Quarterly 10-Q Report - Quartzy
Mustang Bio gets extension for Nasdaq compliance By Investing.com - Investing.com South Africa
Crude Oil Brent (F) (QAX25) Quote - The Globe and Mail
Mustang Bio gets extension for Nasdaq compliance - Investing.com
Mustang Bio Receives Positive Listing Determination from Nasdaq - The Manila Times
Mustang Bio Secures Critical Nasdaq Extension, Faces January 2025 Deadline for $1 Compliance | MBIO Stock News - StockTitan
Virus Therapy Gets Orphan Drug Designation for Glioma Treatment - www.oncnursingnews.com/
Mustang Bio Inc (MBIO) Quarterly 10-Q Report - Quartzy
Mustang Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Mustang Bio’s MB-108 receives FDA orphan drug status for glioma treatment - Yahoo Finance
Toll Brothers Inc (TOL-N) QuotePress Release - The Globe and Mail
Mustang Bio gains FDA Orphan Drug Status for glioma treatment - Investing.com India
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for - GlobeNewswire
Mustang Bio gains FDA Orphan Drug Status for glioma treatment By Investing.com - Investing.com UK
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma - Yahoo Finance
FDA Grants Orphan Drug Designation to MB-108 for Malignant Glioma - OncLive
Mustang Bio sets annual meeting date, deadlines for proposals - Investing.com
Everquote Inc Cl A (EVER-Q) QuotePress Release - The Globe and Mail
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Data Readouts At EHA Congress 2021 (APTO, XFOR, GBT, CRIS…) - RTTNews
Mustang Bio Secures $4M through Strategic Warrant Agreement - Yahoo Finance
Revance Therapeutics Inc’s (RVNC) Stock Is Harder To Predict Than You Think - Stocks Register
Mustang Bio, Inc. Appoints David Jin as A Member of the Board - Marketscreener.com
Mustang Bio secures $4 million from warrant exercises - Investing.com India
Mustang Bio secures $4 million from warrant exercises By Investing.com - Investing.com South Africa
Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds - GlobeNewswire
Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket - Benzinga
FDA Approves Ion Torrent Oncomine Dx Target for Brain Cancer - www.oncnursingnews.com/
Chimeric Antigen Receptor T (CAR-T) Cells Market Research Analysis 2024-2033 | Growth, Size, Analysis, Insi... - WhaTech
Investor’s Toolkit: Key Ratios for Assessing Mustang Bio Inc (MBIO)’s Performance - The Dwinnex
A stock that deserves closer examination: Mustang Bio Inc (MBIO) - US Post News
Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket - MSN
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):